← Browse by Condition

Medical Condition

nsclc

Total Trials

27

Recruiting Now

27

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for nsclc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — nsclc Clinical Trials

How many clinical trials are currently recruiting for nsclc?

ClinicalMetric currently tracks 27 actively recruiting clinical trials for nsclc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 27. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for nsclc?

nsclc research spans Phase 1 (8 trials), Phase 2 (15 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a nsclc clinical trial?

Eligibility criteria for nsclc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

8

Phase 2

15

Phase 3

2

Top Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2 trials

Memorial Sloan Kettering Cancer Center 2 trials

Montefiore Medical Center 1 trial

The First Affiliated Hospital of Guangzhou Medical University 1 trial

Gilead Sciences 1 trial

Recruiting Clinical Trials

NCT06865339 Phase 2

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Montefiore Medical Center

LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer

The First Affiliated Hospital ...

NCT06657222 Phase 1, Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

United States, Canad...

Gilead Sciences

NCT06816992 Phase 1

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

United States, Austr...

ORIC Pharmaceuticals

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Fondazione IRCCS Istituto Nazi...

NCT06107686 Phase 2

A Study of YL202 in Selected Patients With Advanced Solid Tumors

MediLink Therapeutics (Suzhou)...

NCT07397338 Phase 1, Phase 2

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Revolution Medicines, Inc.

NCT06050980 Phase 1

Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

Haisco Pharmaceutical Group Co...

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Hadassah Medical Organization

NCT05443126 Phase 1, Phase 2

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

United States, Franc...

Ellipses Pharma

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

Cancer Institute and Hospital,...

NCT07158489 Phase 2

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

Swiss Cancer Institute

NCT04585490 Phase 3

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

Stanford University

NCT06754644 Phase 3

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Qilu Pharmaceutical Co., Ltd.

NCT05657873 Phase 2

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Memorial Sloan Kettering Cance...

NCT07085182 Phase 2

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

Zibo Municipal Hospital

NCT05786924 Phase 1, Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

United States, Austr...

Institut de Recherches Interna...

NCT07670013 Phase 2

SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study

Second Affiliated Hospital, Zh...

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）

Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site

European Institute of Oncology

NCT07323732 Phase 2

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

Memorial Sloan Kettering Cance...

NCT07181499 Phase 2

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Betta Pharmaceuticals Co., Ltd...

NCT05798845 Phase 2

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Shanghai Chest Hospital

NCT07746388 Phase 2

Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial

University of Maryland, Baltim...

NCT05987644 Phase 1, Phase 2

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT07793500 EARLY_Phase 1

YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)

Cancer Institute and Hospital,...

Related Conditions

non small cell lung cancer (5) lung cancer (3) brain metastases (3) cancer (2) advanced solid tumors (2) hnscc (2) crc (2) nsclc stage iii (2) nsclc stage ii (2) locally advanced (1) lung (1) sclc (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology